These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 24058016)

  • 1. Response to 'Evidence in Support of the Validity of the TNF Brake Hypothesis' by Maksymowych.
    Baraliakos X; Braun J
    Ann Rheum Dis; 2013 Dec; 72(12):e32-3. PubMed ID: 24058016
    [No Abstract]   [Full Text] [Related]  

  • 2. Evidence in support of the validity of the TNF brake hypothesis.
    Maksymowych WP
    Ann Rheum Dis; 2013 Dec; 72(12):e31. PubMed ID: 23989987
    [No Abstract]   [Full Text] [Related]  

  • 3. Treatment of ankylosing spondylitis with infliximab.
    Boeger CA; Wittwer H; Schattenkirchner M; Kellner H; Kellner W
    Ann Rheum Dis; 2001 Dec; 60(12):1159-60. PubMed ID: 11760727
    [No Abstract]   [Full Text] [Related]  

  • 4. [New results from studies of therapy of ankylosing spondylitis with infliximab].
    Braun J
    Z Rheumatol; 2003 Apr; 62(2):108-9. PubMed ID: 12820612
    [No Abstract]   [Full Text] [Related]  

  • 5. Antitumour necrosis factor-α therapy modulates angiopoietin-2 serum levels in non-diabetic ankylosing spondylitis patients.
    Genre F; Miranda-Filloy JA; López-Mejias R; Carnero-López B; Ochoa R; Rueda J; González-Juanatey C; Blanco R; Llorca J; González-Gay MA
    Ann Rheum Dis; 2013 Jul; 72(7):1265-7. PubMed ID: 23482472
    [No Abstract]   [Full Text] [Related]  

  • 6. Inefficacy of infliximab in ankylosing spondylitis is correlated with antibody formation.
    de Vries MK; Wolbink GJ; Stapel SO; de Groot ER; Dijkmans BA; Aarden LA; van der Horst-Bruinsma IE
    Ann Rheum Dis; 2007 Jan; 66(1):133-4. PubMed ID: 17178760
    [No Abstract]   [Full Text] [Related]  

  • 7. Which spinal lesions are associated with new bone formation in patients with ankylosing spondylitis treated with anti-TNF agents? A long-term observational study using MRI and conventional radiography.
    Baraliakos X; Heldmann F; Callhoff J; Listing J; Appelboom T; Brandt J; Van den Bosch F; Breban M; Burmester G; Dougados M; Emery P; Gaston H; Grunke M; Van Der Horst-Bruinsma IE; Landewé R; Leirisalo-Repo M; Sieper J; De Vlam K; Pappas D; Kiltz U; Van Der Heijde D; Braun J
    Ann Rheum Dis; 2014 Oct; 73(10):1819-25. PubMed ID: 23852807
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Infliximab: in ankylosing spondylitis.
    Robinson DM; Keating GM
    Drugs; 2005; 65(9):1283-91; discussion 1292-4. PubMed ID: 15916451
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunological basis for the use of TNFalpha-blocking agents in ankylosing spondylitis and immunological changes during treatment.
    Zou JX; Braun J; Sieper J
    Clin Exp Rheumatol; 2002; 20(6 Suppl 28):S34-7. PubMed ID: 12463444
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Resolution of inflammation following treatment of ankylosing spondylitis is associated with new bone formation.
    Pedersen SJ; Chiowchanwisawakit P; Lambert RG; Østergaard M; Maksymowych WP
    J Rheumatol; 2011 Jul; 38(7):1349-54. PubMed ID: 21459937
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic controversies: tumor necrosis factor α inhibitors in ankylosing spondylitis.
    Song IH; Maksymowych WP
    Rheum Dis Clin North Am; 2012 Aug; 38(3):613-33. PubMed ID: 23083759
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Infliximab-induced palmoplantar psoriasis in a patient with ankylosing spondylitis.
    Capkin E; Karkucak M; Yayli S; Aydin Çapkin A; Tosun M
    J Clin Rheumatol; 2011 Aug; 17(5):293-4. PubMed ID: 21808187
    [No Abstract]   [Full Text] [Related]  

  • 13. Anti-tumour necrosis factor therapy in ankylosing spondylitis. A need for guidelines.
    Kassimos DG; Garyfallos A; Delamere J; Whallett A; Kitas GD
    Rheumatology (Oxford); 2003 Mar; 42(3):490. PubMed ID: 12626807
    [No Abstract]   [Full Text] [Related]  

  • 14. Could tumour necrosis factor blockers inhibit the progression of future structural damage in ankylosing spondylitis?
    Gaspersic N; Sersa I; Jevtic V; Tomsic M; Praprotnik S
    Ann Rheum Dis; 2008 Sep; 67(9):1354. PubMed ID: 18697784
    [No Abstract]   [Full Text] [Related]  

  • 15. Antitumour necrosis factor α treatment reduces retinol-binding protein 4 serum levels in non-diabetic ankylosing spondylitis patients.
    Genre F; López-Mejías R; Miranda-Filloy JA; Ubilla B; Carnero-López B; Gómez-Acebo I; Blanco R; Ochoa R; Rueda-Gotor J; Pina T; González-Juanatey C; Llorca J; González-Gay MA
    Ann Rheum Dis; 2014 May; 73(5):941-3. PubMed ID: 24323393
    [No Abstract]   [Full Text] [Related]  

  • 16. [Anti-TNF alpha in the treatment of rheumatoid arthritis and ankylosing spondylitis].
    Lanfant-Weybel K; Lequerré T; Vittecoq O
    Presse Med; 2009 May; 38(5):774-87. PubMed ID: 19327945
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radiographic progression in patients with ankylosing spondylitis after 2 years of treatment with the tumour necrosis factor alpha antibody infliximab.
    Baraliakos X; Listing J; Rudwaleit M; Brandt J; Sieper J; Braun J
    Ann Rheum Dis; 2005 Oct; 64(10):1462-6. PubMed ID: 15778240
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Persistent reduction of spinal inflammation as assessed by magnetic resonance imaging in patients with ankylosing spondylitis after 2 yrs of treatment with the anti-tumour necrosis factor agent infliximab.
    Sieper J; Baraliakos X; Listing J; Brandt J; Haibel H; Rudwaleit M; Braun J
    Rheumatology (Oxford); 2005 Dec; 44(12):1525-30. PubMed ID: 16091396
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Continuous long-term anti-TNF therapy does not lead to an increase in the rate of new bone formation over 8 years in patients with ankylosing spondylitis.
    Baraliakos X; Haibel H; Listing J; Sieper J; Braun J
    Ann Rheum Dis; 2014 Apr; 73(4):710-5. PubMed ID: 23505240
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [A case of generalized tuberculosis in the use of infliximab (Remicade) in patients with Bekhterev's disease].
    Nekrasov EV; Strelis AK; Ianova GV; Filiniuk OV; Buĭnova LN
    Tuberk Biolezni Legkih; 2009; (8):56-60. PubMed ID: 19803353
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.